论文部分内容阅读
目的探讨二膦酸盐联合白细胞介素-2(IL-2)对体内诱导卵巢癌患者外周血γδT细胞增殖的影响。方法选择山西省肿瘤医院妇科2004年11月至2006年6月收入院的未经任何治疗的上皮性卵巢癌患者28例作为实验组,同期体检健康志愿女性28例为对照组,采用流式细胞仪分别对两组进行外周血总T细胞数、γδT细胞计数测量、比较。实验组行肿瘤细胞减灭术加紫杉醇+卡铂化疗6个疗程常规治疗,4周后测定治疗后外周血总T细胞、γδT细胞计数,并与治疗前进行比较。实验组进行二膦酸盐联合IL-2体外诱导外周血γδT细胞增殖试验,试验阳性患者(20例)行二膦酸盐联合IL-2体内诱导γδT细胞增殖治疗,分别比较诱导前后外周血总T细胞数、γδT细胞计数。结果实验组患者外周血总T细胞数[(1411.6±410.8)/μL]、γδT细胞绝对值[(136.2±114.0)/μL]与相对值[(8.4±5.5)%]均显著低于对照组的(1617.5±488.9)/μL、(175.5±119.1)/μL及(10.2±5.2)%,差异有统计学意义(P<0.05);常规治疗前后卵巢癌患者外周血总T细胞数[(1034.5±336.4)/μL]、γδT细胞计数[(55.7±40.4)/μL]减少,差异有统计学意义(P<0.05);二膦酸盐联合IL-2体内诱导后外周血总T细胞数[(955.6±352.2)/μL、(1415.4±387.4)/μL]、γδT细胞绝对值[(49.2±24.1)/μL、(201.7±53.2)/μL]与相对值[(5.2±1.8)%、(10.1±2.9)%]发生增殖,差异有统计学意义(P<0.05)。结论二膦酸盐联合IL-2可体内诱导卵巢癌患者外周血γδT细胞增殖。
Objective To investigate the effects of bisphosphonate combined with interleukin-2 (IL-2) on the proliferation of γδT cells in peripheral blood of ovarian cancer patients. Methods 28 cases of epithelial ovarian cancer patients who received gynecology and gynecology in Shanxi Cancer Hospital from November 2004 to June 2006 without any treatment were selected as the experimental group and 28 healthy volunteers were selected as the control group in the same period. The two groups were measured the total number of T cells in peripheral blood, γδ T cell count measurement, comparison. The experimental group were treated with paclitaxel + carboplatin chemotherapy for 6 courses of routine therapy. After 4 weeks, the total T cells and γδT count in peripheral blood were measured and compared with those before treatment. In the experimental group, the proliferation of γδT cells in peripheral blood was induced by bisphosphonates combined with IL-2. The positive patients (20 cases) were treated with bisphosphonate combined with IL-2 to induce the proliferation of γδT cells in vivo. T cell number, γδ T cell count. Results The total number of T cells (1411.6 ± 410.8) / μL] and the absolute value of γδT cells (136.2 ± 114.0) / μL and the relative value [(8.4 ± 5.5)%] in experimental group were significantly lower than those in control group (1617.5 ± 488.9) / μL, (175.5 ± 119.1) / μL and (10.2 ± 5.2)%, respectively, the difference was statistically significant (P <0.05). The number of total T cells in peripheral blood of patients with ovarian cancer before and after treatment ± 336.4) / μL], γδT cell count [(55.7 ± 40.4) / μL], the difference was statistically significant (P <0.05); the number of total T cells in peripheral blood induced by bisphosphonate combined with IL- (955.6 ± 352.2) / μL, (1415.4 ± 387.4) / μL] and absolute value of γδT cells [(49.2 ± 24.1) / μL, (201.7 ± 53.2) / μL] and relative values [(5.2 ± 1.8) 10.1 ± 2.9)%] proliferation, the difference was statistically significant (P <0.05). Conclusion Bisphosphonates combined with IL-2 can induce the proliferation of γδT cells in peripheral blood of ovarian cancer patients in vivo.